<DOC>
	<DOCNO>NCT01567358</DOCNO>
	<brief_summary>The purpose study compare safety NI-071 Remicade® ( infliximab ) patient Rheumatoid Arthritis inadequately treat Methotrexate .</brief_summary>
	<brief_title>Study NI-071 Comparison With Remicade Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Diagnosis Rheumatoid Arthritis ( RA ) define 1987 revised American College Rheumatology ( ACR ) criteria ACR Functional Classification class IIII disease duration le 3 month 2 . Patients must receive minimum 3 month treatment methotrexate ( MTX ) ( ≥ 6 mg/week ) prior Screening Visit . Patients must stable dose MTX ( 6 mg~16 mg mg/week ) minimum 4 week prior Screening Visit 1 . History follow diseases Other Connective tissue disorder joint symptom may interfere efficacy assessment Chlonic recurrent infectious disease（bronchial ectasia , sinus inflammation etc.） Severe infectious disease（hepatitis , pneumonia、sepsis） History demyelinate disease multiple sclerosis Congestive heart failure lymphoproliferative disorder myelodysplastic syndrome History malignancy Interstitial lung disease 2 . Patients active latent tuberculosis history tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>